MX2017013382A - Nuevas dihidropiridoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios. - Google Patents
Nuevas dihidropiridoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios.Info
- Publication number
- MX2017013382A MX2017013382A MX2017013382A MX2017013382A MX2017013382A MX 2017013382 A MX2017013382 A MX 2017013382A MX 2017013382 A MX2017013382 A MX 2017013382A MX 2017013382 A MX2017013382 A MX 2017013382A MX 2017013382 A MX2017013382 A MX 2017013382A
- Authority
- MX
- Mexico
- Prior art keywords
- diseases
- treatment
- pharmaceutical compositions
- novel
- dihydropyridoisoquinolinones
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 230000004968 inflammatory condition Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 abstract 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 abstract 1
- 102100033864 G-protein coupled receptor 84 Human genes 0.000 abstract 1
- 101001069589 Homo sapiens G-protein coupled receptor 84 Proteins 0.000 abstract 1
- 230000003915 cell function Effects 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002124 endocrine Effects 0.000 abstract 1
- 208000030172 endocrine system disease Diseases 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 230000002314 neuroinflammatory effect Effects 0.000 abstract 1
- 230000036407 pain Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1506894.3A GB201506894D0 (en) | 2015-04-23 | 2015-04-23 | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| PCT/EP2016/058607 WO2016169911A1 (en) | 2015-04-23 | 2016-04-19 | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017013382A true MX2017013382A (es) | 2017-12-07 |
Family
ID=53488521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017013382A MX2017013382A (es) | 2015-04-23 | 2016-04-19 | Nuevas dihidropiridoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10568879B2 (https=) |
| EP (1) | EP3286191B1 (https=) |
| JP (1) | JP6777652B2 (https=) |
| KR (1) | KR20170139142A (https=) |
| CN (1) | CN107531703B (https=) |
| AR (1) | AR104362A1 (https=) |
| AU (1) | AU2016251517A1 (https=) |
| BR (1) | BR112017022008A2 (https=) |
| CA (1) | CA2983342A1 (https=) |
| CO (1) | CO2017011093A2 (https=) |
| GB (1) | GB201506894D0 (https=) |
| IL (1) | IL255109A0 (https=) |
| MX (1) | MX2017013382A (https=) |
| PH (1) | PH12017501911A1 (https=) |
| RU (1) | RU2017134551A (https=) |
| SG (1) | SG11201708671RA (https=) |
| TW (1) | TW201702243A (https=) |
| WO (1) | WO2016169911A1 (https=) |
| ZA (1) | ZA201706674B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3403649A1 (en) * | 2017-05-16 | 2018-11-21 | Bayer Pharma Aktiengesellschaft | Inhibitors and antagonists of gpr84 for the treatment of endometriosis |
| CN106977483A (zh) * | 2017-06-02 | 2017-07-25 | 遵义医学院 | 一种二氟烷基取代的黄酮醇、异黄酮醇和香豆素类化合物的合成方法 |
| CN118239937A (zh) | 2017-08-09 | 2024-06-25 | 戴纳立制药公司 | 化合物、组合物及方法 |
| DK3676297T3 (da) | 2017-09-01 | 2023-08-14 | Denali Therapeutics Inc | Forbindelser, sammensætninger og fremgangsmåder |
| RU2020119415A (ru) * | 2017-11-15 | 2021-12-16 | Галапагос Нв | Соединения и их фармацевтические композиции для применения при лечении фиброзных заболеваний |
| WO2020007342A1 (zh) * | 2018-07-06 | 2020-01-09 | 中国科学院上海药物研究所 | 联苯磷酸酯类化合物作为gpr84拮抗剂的应用 |
| MA54953A (fr) * | 2019-02-13 | 2021-12-22 | Denali Therapeutics Inc | Composés, compositions et procédés |
| US12091392B2 (en) | 2019-02-13 | 2024-09-17 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| BR112022011237A2 (pt) | 2019-12-19 | 2022-08-30 | Bayer Ag | Derivados de furoindazol |
| WO2021123394A1 (en) | 2019-12-20 | 2021-06-24 | University Of Copenhagen | G protein-coupled receptor modulators and a pharmaceutical composition |
| US12378229B2 (en) | 2021-02-02 | 2025-08-05 | Liminal Biosciences Limited | GPR84 antagonists and uses thereof |
| WO2022179940A1 (en) | 2021-02-23 | 2022-09-01 | Bayer Aktiengesellschaft | Furoindazole derivatives as gpr84 antagonists |
| WO2022218372A1 (zh) * | 2021-04-14 | 2022-10-20 | 武汉人福创新药物研发中心有限公司 | 一种二氢嘧啶并异喹啉酮类衍生物及用途 |
| EP4330260A1 (en) | 2021-04-29 | 2024-03-06 | Bayer Aktiengesellschaft | Furoindazole derivatives as antagonists or inhibitors of gpr84 |
| EP4355743A1 (en) | 2021-06-18 | 2024-04-24 | University of Copenhagen | Polysubstituted 4-hydroxypyridine and 4-hydroxyquinoline derivatives as gpr84 antagonists |
| CN115611944A (zh) | 2021-07-15 | 2023-01-17 | 中国科学院上海药物研究所 | 不对称gpr84拮抗剂及其用途 |
| WO2024083705A1 (en) | 2022-10-18 | 2024-04-25 | Bayer Aktiengesellschaft | Furoindazole derivatives for the treatment of pain |
| USD1117011S1 (en) * | 2024-07-10 | 2026-03-10 | Delta Electronics, Inc. | Charging connector |
| USD1119767S1 (en) * | 2024-07-10 | 2026-03-24 | Delta Electronics, Inc. | Charging connector |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0926148A1 (en) * | 1997-12-23 | 1999-06-30 | Applied Research Systems Ars Holding N.V. | Benzo (C)quinolizine derivatives, their preparation and use as 5-alphareductases inhibitors |
| WO2005050225A2 (en) * | 2003-10-31 | 2005-06-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84) |
| EP1929310A2 (en) | 2005-09-02 | 2008-06-11 | Arena Pharmaceuticals, Inc. | Human g protein-coupled receptor and modulators thereof for the treatment of atherosclerosis and atherosclerotic disease and for the treatment of conditions related to mcp-1 expression |
| WO2012037782A1 (en) | 2010-09-20 | 2012-03-29 | Glaxo Group Limited | Tricyclic compounds, preparation methods, and their uses |
| AR089284A1 (es) * | 2011-12-22 | 2014-08-13 | Galapagos Nv | Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios |
| WO2014095798A1 (en) | 2012-12-20 | 2014-06-26 | Galapagos Nv | Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists) |
| GB201411241D0 (en) * | 2014-06-25 | 2014-08-06 | Galapagos Nv | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
-
2015
- 2015-04-23 GB GBGB1506894.3A patent/GB201506894D0/en not_active Ceased
-
2016
- 2016-04-19 JP JP2017555303A patent/JP6777652B2/ja active Active
- 2016-04-19 KR KR1020177033832A patent/KR20170139142A/ko not_active Withdrawn
- 2016-04-19 AU AU2016251517A patent/AU2016251517A1/en not_active Abandoned
- 2016-04-19 US US15/568,275 patent/US10568879B2/en active Active
- 2016-04-19 RU RU2017134551A patent/RU2017134551A/ru not_active Application Discontinuation
- 2016-04-19 BR BR112017022008-3A patent/BR112017022008A2/pt not_active Application Discontinuation
- 2016-04-19 EP EP16720370.2A patent/EP3286191B1/en active Active
- 2016-04-19 CA CA2983342A patent/CA2983342A1/en not_active Abandoned
- 2016-04-19 WO PCT/EP2016/058607 patent/WO2016169911A1/en not_active Ceased
- 2016-04-19 SG SG11201708671RA patent/SG11201708671RA/en unknown
- 2016-04-19 MX MX2017013382A patent/MX2017013382A/es unknown
- 2016-04-19 CN CN201680023369.1A patent/CN107531703B/zh active Active
- 2016-04-21 TW TW105112490A patent/TW201702243A/zh unknown
- 2016-04-22 AR ARP160101128A patent/AR104362A1/es unknown
-
2017
- 2017-10-04 ZA ZA2017/06674A patent/ZA201706674B/en unknown
- 2017-10-18 IL IL255109A patent/IL255109A0/en unknown
- 2017-10-19 PH PH12017501911A patent/PH12017501911A1/en unknown
- 2017-10-30 CO CONC2017/0011093A patent/CO2017011093A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201708671RA (en) | 2017-11-29 |
| PH12017501911A1 (en) | 2018-03-05 |
| JP6777652B2 (ja) | 2020-10-28 |
| IL255109A0 (en) | 2017-12-31 |
| WO2016169911A1 (en) | 2016-10-27 |
| CA2983342A1 (en) | 2016-10-27 |
| GB201506894D0 (en) | 2015-06-10 |
| AU2016251517A1 (en) | 2017-10-26 |
| CN107531703B (zh) | 2020-09-01 |
| KR20170139142A (ko) | 2017-12-18 |
| US10568879B2 (en) | 2020-02-25 |
| JP2018513180A (ja) | 2018-05-24 |
| US20190062325A1 (en) | 2019-02-28 |
| BR112017022008A2 (pt) | 2018-07-03 |
| CO2017011093A2 (es) | 2018-01-31 |
| TW201702243A (zh) | 2017-01-16 |
| EP3286191A1 (en) | 2018-02-28 |
| AR104362A1 (es) | 2017-07-12 |
| ZA201706674B (en) | 2019-07-31 |
| EP3286191B1 (en) | 2020-07-29 |
| CN107531703A (zh) | 2018-01-02 |
| RU2017134551A (ru) | 2019-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017501911A1 (en) | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| PH12019502853A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis | |
| PH12018501849A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis | |
| PH12019500393A1 (en) | Substituted pyrrolizine compounds and uses thereof | |
| PH12018501068A1 (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| PH12020551501A1 (en) | Oxadiazole transient receptor potential channel inhibitors | |
| MY170260A (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| PH12020550616A1 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases | |
| MX389592B (es) | Moduladores alostericos positivos del receptor m1 muscarinico | |
| PH12013501557A1 (en) | Glucagon receptor modulator | |
| GEP20217242B (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors | |
| PH12014501178A1 (en) | Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| PH12020550230A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| PH12016501977A1 (en) | 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES | |
| MX2017014035A (es) | Formas solidas novedosas. | |
| IN2014CN02364A (https=) | ||
| MX2019007088A (es) | Derivados de la pirimidin enona tricíclica para la inhibición de rory y otros usos. | |
| EA201700042A1 (ru) | Соединения имидазопиридазина | |
| PH12021552375A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| SG10201907289VA (en) | Monomethylfumarate prodrug compositions | |
| PH12021552377A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| MX2015011536A (es) | Nuevos antagonistas de receptores trpa1 de sulfamidas. | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
| NZ737892A (en) | Muscarinic m1 receptor positive allosteric modulators | |
| ZA202001295B (en) | Thiazolopyridine derivatives as adenosine receptor antagonists |